Abstract 1788
Background
PET/CT is an essential component in the initial assessment of locally advanced NSCLC. However, the role of PET/CT in the assessment of response to therapies is not well established.
Methods
We reviewed all stage III NSCLC patients assessed at our centre between January 2009 and March 2018, selecting those with PET/CT evaluation at diagnosis and after treatment (chemotherapy and/or radiotherapy). We evaluated the prognostic differences between mayor PET/CT response (reduction of ≥ 50% of initial SUVmax), minor PET response (reduction of < 50%) and absence of response, by Cox regression. We assessed the predictive value of PET/CT for pathological response in both tumour and mediastinal nodes in patients who had undergone surgery after an induction treatment.
Results
We reviewed 249 patients. In 92,3% an initial PET/CT evaluation was carried out. 117 patients (46.9%) had a PET/CT re-evaluation after an initial chemotherapy and/or radiotherapy treatment. We observed a higher risk of disease progression in patients with a minor PET/CT response (HR 1.97; IC95% 1.2-3.2) and without a response (HR 2.3; IC95% 1.4-4.6, p < 0.01). Progression free survival (PFS) at 12 months was 73%, 47% and 32% among patients with a mayor response, a minor response and no response, respectively. Differences in overall survival (OS) did not reach statistical significance (p = 0,06), but a higher risk for death was seen with a minor response (HR 1.7; IC95%, 1-2,9) and no response (HR 2.1; IC95%, 1,2-3,9). 37 patients (14.9%) underwent surgery after an induction treatment. A greater reduction of SUVmax was observed when pathological response was achieved (mean SUVmax reduction of 94% with complete pathological response vs 27% in absence of response). 22 patients with N2 disease pre-induction therapy underwent surgery. SUVmax reduction was higher in patients with a response (60% vs 35%). However, post-induction mediastinal SUVmax > 2.5 presented a sensitivity of only 42.9% and a specificity of 87.5%.
Conclusions
PET/CT response after induction therapy was a good prognosticator for PFS and OS in stage III NSCLC patients. However, response evaluation by PET/CT should be interpreted with caution due to its lack of precision.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Calvo de Juan: Honoraria (self): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Boerhinger; Honoraria (self): Roche. M. Provencio: Honoraria (self), Research grant / Funding (institution): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boerhinger. All other authors have declared no conflicts of interest.
Resources from the same session
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract